HK1120216A1 - The use of bupropion metabolites for the treatment of inflammatory disorders - Google Patents

The use of bupropion metabolites for the treatment of inflammatory disorders

Info

Publication number
HK1120216A1
HK1120216A1 HK08113094.0A HK08113094A HK1120216A1 HK 1120216 A1 HK1120216 A1 HK 1120216A1 HK 08113094 A HK08113094 A HK 08113094A HK 1120216 A1 HK1120216 A1 HK 1120216A1
Authority
HK
Hong Kong
Prior art keywords
treatment
inflammatory disorders
bupropion metabolites
bupropion
metabolites
Prior art date
Application number
HK08113094.0A
Other languages
English (en)
Inventor
John Brew
Robin Mark Bannister
Andrew Douglas Baxter
Original Assignee
Biocopea Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocopea Ltd filed Critical Biocopea Ltd
Publication of HK1120216A1 publication Critical patent/HK1120216A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK08113094.0A 2006-03-09 2008-12-01 The use of bupropion metabolites for the treatment of inflammatory disorders HK1120216A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0604824.3A GB0604824D0 (en) 2006-03-09 2006-03-09 The treatment of inflammatory disorders
PCT/GB2007/000868 WO2007102019A1 (en) 2006-03-09 2007-03-09 The use of bupropion metabolites for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
HK1120216A1 true HK1120216A1 (en) 2009-03-27

Family

ID=36241340

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08113094.0A HK1120216A1 (en) 2006-03-09 2008-12-01 The use of bupropion metabolites for the treatment of inflammatory disorders

Country Status (20)

Country Link
US (1) US8030357B2 (ja)
EP (1) EP1993524B1 (ja)
JP (1) JP5106428B2 (ja)
KR (1) KR20090023546A (ja)
CN (1) CN101415410B (ja)
AT (1) ATE456949T1 (ja)
AU (1) AU2007222217B2 (ja)
BR (1) BRPI0708633A2 (ja)
CA (1) CA2646884A1 (ja)
DE (1) DE602007004664D1 (ja)
DK (1) DK1993524T3 (ja)
ES (1) ES2340816T3 (ja)
GB (1) GB0604824D0 (ja)
HK (1) HK1120216A1 (ja)
IL (1) IL193945A0 (ja)
MX (1) MX2008011507A (ja)
NO (1) NO20083871L (ja)
PL (1) PL1993524T3 (ja)
PT (1) PT1993524E (ja)
WO (1) WO2007102019A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0624757D0 (en) * 2006-12-12 2007-01-17 Sosei R & D Ltd Novel compounds
SI2451452T1 (sl) * 2009-07-08 2015-12-31 Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. - S.P.A. Uporaba benzidamina pri zdravljenju bolezni, odvisnih od p40
GB2484977A (en) * 2010-10-29 2012-05-02 Biocopea Ltd Treatment of a Th-1 mediated disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US20040002546A1 (en) * 2001-09-15 2004-01-01 Eric Altschuler Methods for treating crohn's and other TNF associated diseases
US20050234024A1 (en) * 2004-04-14 2005-10-20 Clarke David E Materials and methods for the treatment of ulcerative colitis
GB0519274D0 (en) * 2005-09-21 2005-11-02 Arakis Ltd The treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
JP2009529520A (ja) 2009-08-20
MX2008011507A (es) 2008-10-23
KR20090023546A (ko) 2009-03-05
JP5106428B2 (ja) 2012-12-26
PT1993524E (pt) 2010-05-10
US8030357B2 (en) 2011-10-04
EP1993524B1 (en) 2010-02-03
CA2646884A1 (en) 2007-09-13
AU2007222217B2 (en) 2010-08-12
ES2340816T3 (es) 2010-06-09
AU2007222217A1 (en) 2007-09-13
US20090318562A1 (en) 2009-12-24
CN101415410B (zh) 2011-01-19
DK1993524T3 (da) 2010-05-31
EP1993524A1 (en) 2008-11-26
CN101415410A (zh) 2009-04-22
ATE456949T1 (de) 2010-02-15
GB0604824D0 (en) 2006-04-19
PL1993524T3 (pl) 2010-07-30
WO2007102019A1 (en) 2007-09-13
DE602007004664D1 (de) 2010-03-25
NO20083871L (no) 2008-10-07
IL193945A0 (en) 2009-08-03
BRPI0708633A2 (pt) 2011-06-14

Similar Documents

Publication Publication Date Title
MX2009007075A (es) Metodos de uso para analogos de ciclopamina.
EA200700757A1 (ru) Замещённые дипиперидиновые антагонисты ccr2
MX2009007180A (es) Agonistas del receptor acoplado a la proteina g de la piperidina.
TW200738688A (en) Compounds for the treatment of inflammatory disorders
EA200900877A1 (ru) Пиперидиновые агонисты gpcr
TW200738725A (en) Unsaturated mTOR inhibitors
SG170024A1 (en) Imidazole-based compounds, compositions comprising them and methods of their use
MX2010002312A (es) Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis.
SI1725544T1 (sl) 3-(4-heterociklil-1,2,3-triazol-1-il)-N-aril-benzamidi kot inhibitorji proizvodnje citokinov za zdravljenje kroničnih vnetnih bolezni
TN2011000291A1 (en) Purine compounds
GB0812642D0 (en) Compounds
WO2007142905A3 (en) 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands
MX2008001546A (es) 3,11b-cis-dihidrotetrabenazina para el tratamiento de una enfermedad proliferativa o una inflamacion.
MX2011011776A (es) Nuevos profarmacos de triptolite.
SG154441A1 (en) Treatment of demyelinating disorders
WO2009082526A3 (en) Ortho pyrrolidine, benzyl-substituted heterocycle ccr1 antagonists for autoimmune diseases & inflammation
MY152557A (en) 3-aminocyclopentanecarboxamides as chemokine receptor modulators
MX2008002158A (es) Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6.
UA94053C2 (ru) Замещенные производные 3-сульфонилиндазола в качестве лигандов гидрокситриптамина-6
HK1120216A1 (en) The use of bupropion metabolites for the treatment of inflammatory disorders
UA94781C2 (ru) Применение йота-каррагенана для профилактики или терапевтического лечения риновирусной инфекции
TW200606148A (en) Indolylalkylamine metabolites as 5-hydroxytryptamine-6 ligands
MX2008011508A (es) El uso de beta-aminoalcoholes para el tratamiento de desordenes inflamatorios y dolor.
WO2008006363A3 (de) Behandlung von t-zell-malignomen mit bcl11b-inhibitoren
WO2009073138A3 (en) Treatment of metabolic syndrome with novel amides

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140309